<DOC>
	<DOC>NCT00631475</DOC>
	<brief_summary>This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF).</brief_summary>
	<brief_title>Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Patients should have completed all the assessments from the BUILD 3 (NCT00391443) end of study (EOS) visit. Signed informed consent prior to initiation of any studyrelated procedures. Women of childbearing potential must have a negative serum pregnancy test and use reliable methods of contraception during study treatment and for 3 months after study treatment termination. Any major violation of protocol AC052321 / BUILD 3 (NCT00391443). Pregnancy or breastfeeding. AST and/or ALT &gt; 3 times the upper limit of the normal range. Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence or psychiatric disease. Known hypersensitivity to bosentan or any of the excipients.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Actelion</keyword>
	<keyword>Idiopathic Pulmonary Fibrosis</keyword>
	<keyword>bosentan</keyword>
	<keyword>Tracleer</keyword>
	<keyword>Interstitial Lung Disease</keyword>
	<keyword>BUILD 3 (NCT00391443)</keyword>
</DOC>